Altered pharmacology and distinct coactivator usage for estrogen receptor-dependent transcription through activating protein-1

Edwin Cheung, Mari Luz Acevedo, Philip A. Cole, W. Lee Kraus

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Estrogen signaling occurs through at least two distinct molecular pathways: (i) direct binding of liganded estrogen receptors (ERs) to estrogen-responsive DMA elements (EREs) (the "ER ERE pathway") and (ii) indirect recruitment of liganded ERs to activating protein-1 (AP-1)-responsive DMA elements via heterodimers of Fos and Jun (the "ER AP-1 pathway"). We have developed a biochemical assay for examining ligand-regulated transcription by ERs in the ER/AP-1 pathway. This assay recapitulates the altered (i.e., agonistic) pharmacology of selective estrogen receptor modulator drugs in this pathway reported previously by using various cell-based assays. We used our biochemical assay to examine the detailed mechanisms of ER/AP-1-dependent transcription. Our studies indicate that (i) ERα AP-1 complexes play a critical role in promoting the formation of stable RNA polymerase II preinitiation complexes leading to transcription initiation, (ii) chromatin is a key determinant of estrogen and selective estrogen receptor modulator signaling in the EIRα, AP-1 pathway, (iii) distinct domains of ERα are required for recruitment to DMA-bound Fos/Jun heterodimers and transcriptional activation at AP-1 sites, and (iv) different enhancer/activator combinations in the ERα and AP-1 pathways use coactivators in distinct ways. These studies have increased our understanding of the molecular mechanisms underlying ligand-dependent signaling in the ER/AP-1 pathway and demonstrate the usefulness of this biochemical approach.

Original languageEnglish (US)
Pages (from-to)559-564
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume102
Issue number3
DOIs
StatePublished - Jan 18 2005

Fingerprint

Estrogen Receptors
Pharmacology
Estrogens
Selective Estrogen Receptor Modulators
Proteins
Ligands
RNA Polymerase II
Transcriptional Activation
Chromatin
estrophilin
Pharmaceutical Preparations

Keywords

  • Chromatin
  • Enhancer
  • Fos/Jun heterodimers
  • Histone acetyltransferase
  • Selective estrogen receptor modulator

ASJC Scopus subject areas

  • Genetics
  • General

Cite this

Altered pharmacology and distinct coactivator usage for estrogen receptor-dependent transcription through activating protein-1. / Cheung, Edwin; Acevedo, Mari Luz; Cole, Philip A.; Kraus, W. Lee.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 102, No. 3, 18.01.2005, p. 559-564.

Research output: Contribution to journalArticle

@article{91e866bef91849928443f9df3b022586,
title = "Altered pharmacology and distinct coactivator usage for estrogen receptor-dependent transcription through activating protein-1",
abstract = "Estrogen signaling occurs through at least two distinct molecular pathways: (i) direct binding of liganded estrogen receptors (ERs) to estrogen-responsive DMA elements (EREs) (the {"}ER ERE pathway{"}) and (ii) indirect recruitment of liganded ERs to activating protein-1 (AP-1)-responsive DMA elements via heterodimers of Fos and Jun (the {"}ER AP-1 pathway{"}). We have developed a biochemical assay for examining ligand-regulated transcription by ERs in the ER/AP-1 pathway. This assay recapitulates the altered (i.e., agonistic) pharmacology of selective estrogen receptor modulator drugs in this pathway reported previously by using various cell-based assays. We used our biochemical assay to examine the detailed mechanisms of ER/AP-1-dependent transcription. Our studies indicate that (i) ERα AP-1 complexes play a critical role in promoting the formation of stable RNA polymerase II preinitiation complexes leading to transcription initiation, (ii) chromatin is a key determinant of estrogen and selective estrogen receptor modulator signaling in the EIRα, AP-1 pathway, (iii) distinct domains of ERα are required for recruitment to DMA-bound Fos/Jun heterodimers and transcriptional activation at AP-1 sites, and (iv) different enhancer/activator combinations in the ERα and AP-1 pathways use coactivators in distinct ways. These studies have increased our understanding of the molecular mechanisms underlying ligand-dependent signaling in the ER/AP-1 pathway and demonstrate the usefulness of this biochemical approach.",
keywords = "Chromatin, Enhancer, Fos/Jun heterodimers, Histone acetyltransferase, Selective estrogen receptor modulator",
author = "Edwin Cheung and Acevedo, {Mari Luz} and Cole, {Philip A.} and Kraus, {W. Lee}",
year = "2005",
month = "1",
day = "18",
doi = "10.1073/pnas.0407113102",
language = "English (US)",
volume = "102",
pages = "559--564",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "3",

}

TY - JOUR

T1 - Altered pharmacology and distinct coactivator usage for estrogen receptor-dependent transcription through activating protein-1

AU - Cheung, Edwin

AU - Acevedo, Mari Luz

AU - Cole, Philip A.

AU - Kraus, W. Lee

PY - 2005/1/18

Y1 - 2005/1/18

N2 - Estrogen signaling occurs through at least two distinct molecular pathways: (i) direct binding of liganded estrogen receptors (ERs) to estrogen-responsive DMA elements (EREs) (the "ER ERE pathway") and (ii) indirect recruitment of liganded ERs to activating protein-1 (AP-1)-responsive DMA elements via heterodimers of Fos and Jun (the "ER AP-1 pathway"). We have developed a biochemical assay for examining ligand-regulated transcription by ERs in the ER/AP-1 pathway. This assay recapitulates the altered (i.e., agonistic) pharmacology of selective estrogen receptor modulator drugs in this pathway reported previously by using various cell-based assays. We used our biochemical assay to examine the detailed mechanisms of ER/AP-1-dependent transcription. Our studies indicate that (i) ERα AP-1 complexes play a critical role in promoting the formation of stable RNA polymerase II preinitiation complexes leading to transcription initiation, (ii) chromatin is a key determinant of estrogen and selective estrogen receptor modulator signaling in the EIRα, AP-1 pathway, (iii) distinct domains of ERα are required for recruitment to DMA-bound Fos/Jun heterodimers and transcriptional activation at AP-1 sites, and (iv) different enhancer/activator combinations in the ERα and AP-1 pathways use coactivators in distinct ways. These studies have increased our understanding of the molecular mechanisms underlying ligand-dependent signaling in the ER/AP-1 pathway and demonstrate the usefulness of this biochemical approach.

AB - Estrogen signaling occurs through at least two distinct molecular pathways: (i) direct binding of liganded estrogen receptors (ERs) to estrogen-responsive DMA elements (EREs) (the "ER ERE pathway") and (ii) indirect recruitment of liganded ERs to activating protein-1 (AP-1)-responsive DMA elements via heterodimers of Fos and Jun (the "ER AP-1 pathway"). We have developed a biochemical assay for examining ligand-regulated transcription by ERs in the ER/AP-1 pathway. This assay recapitulates the altered (i.e., agonistic) pharmacology of selective estrogen receptor modulator drugs in this pathway reported previously by using various cell-based assays. We used our biochemical assay to examine the detailed mechanisms of ER/AP-1-dependent transcription. Our studies indicate that (i) ERα AP-1 complexes play a critical role in promoting the formation of stable RNA polymerase II preinitiation complexes leading to transcription initiation, (ii) chromatin is a key determinant of estrogen and selective estrogen receptor modulator signaling in the EIRα, AP-1 pathway, (iii) distinct domains of ERα are required for recruitment to DMA-bound Fos/Jun heterodimers and transcriptional activation at AP-1 sites, and (iv) different enhancer/activator combinations in the ERα and AP-1 pathways use coactivators in distinct ways. These studies have increased our understanding of the molecular mechanisms underlying ligand-dependent signaling in the ER/AP-1 pathway and demonstrate the usefulness of this biochemical approach.

KW - Chromatin

KW - Enhancer

KW - Fos/Jun heterodimers

KW - Histone acetyltransferase

KW - Selective estrogen receptor modulator

UR - http://www.scopus.com/inward/record.url?scp=14144249678&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14144249678&partnerID=8YFLogxK

U2 - 10.1073/pnas.0407113102

DO - 10.1073/pnas.0407113102

M3 - Article

C2 - 15642950

AN - SCOPUS:14144249678

VL - 102

SP - 559

EP - 564

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 3

ER -